Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Monasterio

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Medicina Clinica|February 25, 1984
[Value of antithrombin III determination in chronic liver diseases]M Monreal, J Monasterio, R Rodríguez, et al.
Medicina Clinica|February 25, 1984
[Comparative value of prothrombin time and antithrombin III determinations in the diagnosis of liver cirrhosis]M Monreal, J Monasterio, R Rodríguez, et al.
Archivos De La Sociedad Espanola De Oftalmologia|April 9, 2024
Ultravit high-speed vitrectomy, is higher always better? Hydrodynamic cavitation must be consideredJ Monasterio Bel, E Pérez-Salvador García, A Alcuaz Alcalaya, et al.
Acta Neurologica Scandinavica|December 1, 1987
Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacksJ Matías-Guiu, A Dávalos, M Picó, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 11, 1998
Heparin cofactor II: a new marker for pre-eclampsiaJ Bellart, R Gilabert, L Cabero, et al.
British Journal of Haematology|May 1, 1981
Acquired von Willebrand's disease caused by a chronic granulocytic leukaemiaJ R Duran-Saurez, M Pico, J Zuazu, et al.
Blood|July 1, 1971
Congenital abnormality of the prothrombin molecule (factor II) in four siblings: prothrombin BarcelonaF Josso, J Monasterio de Sanchez, J M Lavergne, et al.
Revista Clinica Espanola|May 1, 1993
[Platelet hyperactivity in diabetic retinopathy: etiologic factor or epiphenomenon of microangiopathy?]L García Pascual, R Simó, J Monasterio, et al.
Medicina Clinica|March 1, 1982
[Heparin at reduced dosage does not change serum lipids]S Masdeu, A M Cortada, A Casals, et al.
Haemostasis|January 1, 1991
Comparative study on the antithrombotic efficacy of four low-molecular-weight heparins in three different models of experimental venous thrombosisM Monreal, P Silveira, L Monreal, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Medicina Clinica|February 25, 1984
[Value of antithrombin III determination in chronic liver diseases]M Monreal, J Monasterio, R Rodríguez, et al.
Medicina Clinica|February 25, 1984
[Comparative value of prothrombin time and antithrombin III determinations in the diagnosis of liver cirrhosis]M Monreal, J Monasterio, R Rodríguez, et al.
Archivos De La Sociedad Espanola De Oftalmologia|April 9, 2024
Ultravit high-speed vitrectomy, is higher always better? Hydrodynamic cavitation must be consideredJ Monasterio Bel, E Pérez-Salvador García, A Alcuaz Alcalaya, et al.
Acta Neurologica Scandinavica|December 1, 1987
Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacksJ Matías-Guiu, A Dávalos, M Picó, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|June 11, 1998
Heparin cofactor II: a new marker for pre-eclampsiaJ Bellart, R Gilabert, L Cabero, et al.
British Journal of Haematology|May 1, 1981
Acquired von Willebrand's disease caused by a chronic granulocytic leukaemiaJ R Duran-Saurez, M Pico, J Zuazu, et al.
Blood|July 1, 1971
Congenital abnormality of the prothrombin molecule (factor II) in four siblings: prothrombin BarcelonaF Josso, J Monasterio de Sanchez, J M Lavergne, et al.
Revista Clinica Espanola|May 1, 1993
[Platelet hyperactivity in diabetic retinopathy: etiologic factor or epiphenomenon of microangiopathy?]L García Pascual, R Simó, J Monasterio, et al.
Medicina Clinica|March 1, 1982
[Heparin at reduced dosage does not change serum lipids]S Masdeu, A M Cortada, A Casals, et al.
Haemostasis|January 1, 1991
Comparative study on the antithrombotic efficacy of four low-molecular-weight heparins in three different models of experimental venous thrombosisM Monreal, P Silveira, L Monreal, et al.
Pageof 5